深圳商报·读创客户端记者 穆砚 12月17日晚间，江苏诺泰澳赛诺生物制药股份有限公司（以下简称"ST诺泰""诺泰生物"或"公司"）发布 关于收到《行政处罚决定书》的公告。公告显示，中国证监会调查认定，ST诺泰在上市首年即通过一 笔缺乏商业实质的技术转让交易虚增利润，粉饰报表，并基于此虚假财务数据成功实施可转债发行，最 终因信息披露违法违规及欺诈发行行为，公司及相关责任人总计被处以73200万元罚款。与此同时，上 海证券交易所对ST诺泰及相关人员予以公开谴责，并限制其五年内再融资资格。此次处罚也为近期持 续发酵的ST诺泰信披违规案画上了阶段性句号。 公告披露，公司于2024年10月24日在上海证券交易所官网披露《关于公司及实际控制人之一收到中国证 券监督管理委员会立案告知书的公告》，公司收到中国证监会《立案告知书》，因公司涉嫌信息披露违 法违规等，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决 定对公司立案。 公司于2025年7月19日在上海证券交易所官网披露《关于收到行政处罚事先告知书的公告》，公司收到 中国证监会下发的《行政处罚事先告知书》。 公司于近日收到中国证监会下发的 ...

2025.12. 17 本文字数：1193，阅读时长大约2分钟 作者 | 第一财经 林志吟 在科创板上市首年，就策划了业绩造假，并且凭借粉饰后的报表，顺利再融资4.34亿元，这样"铤而 走险"的事情就发生在医药外包企业ST诺泰（688076.SH）身上。 12月17日，ST诺泰发布公告称，公司收到中国证监会（下称证监会）下发的《行政处罚决定书》以 及上海证券交易所（下称上交所）予以纪律处分的决定。 ST诺泰主要从事多肽药物及小分子化药自主研发与定制研发生产。2021年5月20日，公司登陆科创 板上市。ST诺泰曾是A股中市场红极一时的减肥药概念股。 2021年12月，ST诺泰向浙江华贝药业有限责任公司（以下简称浙江华贝）转让药品技术及上市持 有许可人权益（以下简称技术转让），并于12月28日确认业务收入3000万元。浙江华贝既不具备支 付技术转让款的资金实力，也不具备实际应用该技术的生产能力和销售渠道。同期，ST诺泰策划向 浙江华贝增资。浙江华贝向ST诺泰支付的技术转让款最终来自ST诺泰的增资款。 ST诺泰技术转让业务不具有商业实质，不应确认收入。该业务导致诺泰生物2021年年度报告虚增营 业收入3000万元， ...

在科创板上市首年，就策划了业绩造假，并且凭借粉饰后的报表，顺利再融资4.34亿元，这样"铤而走 险"的事情就发生在医药外包企业ST诺泰（688076.SH）身上。 12月17日，ST诺泰发布公告称，公司收到中国证监会（下称证监会）下发的《行政处罚决定书》以及 上海证券交易所（下称上交所）予以纪律处分的决定。 ST诺泰主要从事多肽药物及小分子化药自主研发与定制研发生产。2021年5月20日，公司登陆科创板上 市。ST诺泰曾是A股中市场红极一时的减肥药概念股。 经过证监会的调查，ST诺泰存在两大违法事实，一是2021年年度报告存在虚假记载；二是公开发行文 件编造重大虚假内容。 在ST诺泰上市后的第二年，公司启动了再融资事项。 2022年11月16日，ST诺泰召开第三届董事会第七次会议，审议通过了关于向不特定对象发行可转换公 司债券的相关议案。 与此同时，上交所纪律处分委员会经审核认为ST诺泰披露的定期报告存在虚假记载，且公开发行文件 编造重大虚假内容，构成欺诈发行，行为严重扰乱证券市场秩序、损害投资者知情权，违规情节严重。 两大监管机构对ST诺泰以及参与业绩造假的人员进行了处罚。 2021年12月，ST诺泰向浙江 ...

9月15日，Luca de Meo临危受命出任开云CEO。这位58岁的意大利裔经理人上任后大刀阔斧改革，先是 宣布延迟收购华伦天奴，又将高级香水品牌Creed以及旗下标志性品牌的美妆与香水授权打包作价40亿 欧元卖给欧莱雅。 值得注意的是，华伦天奴目前的美妆和香水业务同样授权欧莱雅运营，去年该板块表现强劲，营收同比 增长51%，线上销售增长5%，占全年收入的70%。上述数字表明，华伦天奴品牌仍有增长潜力，但核心 的成衣业务拖累了整体表现。 新快报记者 陆妍思 此次"被寄信"的开云集团，于2023年以17亿欧元在卡塔尔投资基金Mayhoola手上收购了其持有的华伦天 奴30%股份，并获得了在2026年和2027年收购剩余70%股份的期权。不过，开云集团于今年9月宣布， 上述收购期权将推迟到2029年。 开云集团在其年度报告中表示，全面收购华伦天奴将耗资约40亿欧元，但以该品牌收益的倍数计算，这 个数字可能会有所不同。根据华伦天奴公布的财务数据，2024年度营业收入为13.1亿欧元，按固定汇率 计算较上年同期减少2%，全年营业利润同比更暴跌22%，仅为2.46亿欧元。其2025年上半年利润进一步 恶化，一度触发债 ...

为了不错过我们的推文，大家可以将我们「星标置顶」， 这样你看到我们推送的概率也会更高一些哦~ 此外，还曾以"工作效率追踪"为名实施员工监控，该行为直至今年2月港澳台地区员工集体抗议后才得以终止。 12月1日消息，华伦天奴大中华区员工近日向品牌总部及股东开云集团发送举报信，指控首席执行官Janice Lam（林讯 甄）存在业绩造假、职场霸凌等行为。 举报材料显示，自2022年上任以来，其为提升业绩指标采取非常规销售手段。具体操作包括由公司承担成本进行折扣促 销、利用员工折扣资格向客户销售商品，以及冒用合作伙伴名义开展促销活动。 这些做法虽短期内美化业绩，却对品牌长期声誉造成损害。在管理风格方面，举报员工指出其在团队会议中经常使用侮 辱性语言，通过制造恐惧氛围压制不同意见。 据悉，员工自今年初已三次向品牌总部提交举报材料，最近一次发生在9月。总部曾在5月启动内部审计程序，原定7月来 华的前首席执行官因离职未能成行。 员工担心在集团人事变动期间，此事可能被搁置。目前举报材料已同步发送给大股东开云集团。 2022年4月，Valentino宣布林汛甄（Janice Lam）出任大中华区首席执行官，将暂时向首席执行官 J ...

12月1日消息，华伦天奴大中华区员工近日向品牌总部及股东开云集团发送举报信，指控首席执行官Janice Lam（林讯甄）存在业绩造假、职场霸凌等行 为。 举报材料显示，自2022年上任以来，其为提升业绩指标采取非常规销售手段。具体操作包括由公司承担成本进行折扣促销、利用员工折扣资格向客户销售 商品，以及冒用合作伙伴名义开展促销活动。 这些做法虽短期内美化业绩，却对品牌长期声誉造成损害。在管理风格方面，举报员工指出其在团队会议中经常使用侮辱性语言，通过制造恐惧氛围压制 不同意见。 2022年4月，Valentino宣布林汛甄（Janice Lam）出任大中华区首席执行官，将暂时向首席执行官 Jacopo Venturin 汇报工作。她将致力于推动品牌在大中华 区的发展、制定品牌战略方向以及促进零售业务的增长等。同时其将在总部的支持下，专注以顾客和员工为中心的战略，运用高级定制的顾客体验和数字 转型的发展。在加入 Valentino 前，林汛甄曾担任过历峰集团旗下品牌 Dunhill 中国区总经理以及Prada 中国区总经理。（往期阅读：） 【中国服装圈.第3337期】来源：网易新闻 此外，还曾以"工作效率追踪" ...

Core Viewpoint - The article discusses the fraudulent practices of Nohow Health, revealing how the company manipulated sales data and engaged in deceptive activities that led to its impending liquidation and delisting from the stock market [1][23]. Group 1: Fraudulent Practices - Nohow Health was accused of fabricating sales performance, with claims that 90% of its sales revenue was artificially inflated through various deceptive methods, including purchasing fecal samples from sanitation workers [4][8]. - The company utilized a network of third-party firms to facilitate these fraudulent transactions, creating a "virtual sale" environment where actual customer transactions were not necessary [9][11]. - The sales team expanded significantly, from about 100 employees in early 2021 to nearly 500 by 2022, which contributed to a 260% revenue increase, raising sales from 200 million to 760 million [12]. Group 2: Internal Knowledge and Accountability - Key executives, including the company's main leaders, were aware of and led the fraudulent activities, with only a select few high-ranking officials allowed to attend confidential sales strategy meetings [4][16]. - The company attempted to cover up its fraudulent activities by planning to falsify financial reports for 2024, which ultimately led to the withdrawal of Deloitte's audit support [4][18]. Group 3: Market Reaction and Consequences - Following the release of a short-selling report, Nohow Health's stock price plummeted from a peak of 38.95 HKD to 15.7 HKD, with trading volume surging to over 28 million shares on that day [18][19]. - The company is now undergoing a liquidation process, with the board of directors losing actual decision-making power, and the delisting appears inevitable [23]. Group 4: Investor Impact - Over 4,000 individual investors have registered to seek compensation, with total investments exceeding 700 million, highlighting the significant financial impact on public investors [24].

Core Viewpoint - Meicheng Technology faces administrative penalties due to false financial reporting, with a cumulative inflated revenue of 1.438 billion yuan and inflated profits of 658 million yuan from 2014 to 2018 [3][8][9]. Financial Misreporting - The company reported inflated revenues of 23.66 million yuan, 373 million yuan, 726 million yuan, 215 million yuan, and 101 million yuan for the years 2014 to 2018, respectively, accounting for 2.06%, 20.67%, 24.60%, 5.53%, and 2.88% of the disclosed revenue for those years [8]. - The inflated profits for the same years were 22.93 million yuan, 189 million yuan, 260 million yuan, 117 million yuan, and 69.49 million yuan, representing 17.91%, 75.64%, 49.78%, 15.49%, and 15.58% of the disclosed profit totals [8]. Regulatory Actions - The Shandong Securities Regulatory Bureau has proposed a fine of 600,000 yuan for the company and a total of 2.3 million yuan for 12 responsible individuals, including a 10-year market ban for Guo Baifeng, the former chairman of the subsidiary involved in the fraud [9][10]. - Starting September 30, the company's stock will be marked with a risk warning and will change its name to ST Meicheng, while the stock code remains the same [10][11]. Financial Performance - Meicheng Technology has reported continuous losses for four consecutive years from 2021 to 2024, with a total loss amounting to 3.683 billion yuan [12][13]. - The company attributes its ongoing losses primarily to declining performance in its landscaping business and difficulties in project payment collections [16]. Asset Disposal Strategy - To mitigate losses, Meicheng Technology is in the process of selling off its loss-making assets, particularly those related to the landscaping business [17]. - The company plans to divest 100% of its stake in the subsidiary, Saisiyuanlin, and has already initiated the transfer of several related companies [17]. Market Position - As of September 26, Meicheng Technology's stock closed at 3.22 yuan per share, with a market capitalization of 4.643 billion yuan [18].

Core Viewpoint - The Shenzhen Stock Exchange has publicly reprimanded Jinglan Technology Co., Ltd. and related parties for violations related to financial reporting and performance commitments [2][4]. Group 1: Violations and Disciplinary Actions - Jinglan Technology entered into an agreement in September 2018 to acquire 56.7152% of the shares of its subsidiary Zhongke Dingshi Environmental Engineering Co., Ltd. through a share issuance, with performance commitments to achieve a cumulative net profit of no less than 40 million yuan from 2018 to 2020 [2]. - In 2020, Zhongke Dingshi falsely recognized project completion and inflated revenue, costs, and profits to meet performance commitments, leading to significant misstatements in Jinglan Technology's annual report [3]. - The inflated figures included an increase in operating revenue by 162.91 million yuan (14.06% of reported revenue), operating costs by 96.55 million yuan (4.3% of reported costs), total profit by 66.36 million yuan (2.67% of total profit), and net profit by 57.71 million yuan (2.27% of net profit) [3]. Group 2: Disciplinary Measures - The Shenzhen Stock Exchange has decided to publicly reprimand Jinglan Technology and its former executives, including the chairman, president, vice president, and financial officer, for their roles in the violations [5]. - The disciplinary actions are based on the company's failure to adhere to the Stock Listing Rules and the lack of diligence and integrity from the executives involved [4][5]. - The company and the individuals have the right to apply for a review of the disciplinary decision within fifteen trading days [5].

Core Viewpoint - China Evergrande Group has been delisted from the Hong Kong Stock Exchange due to failure to meet the resumption requirements, marking the end of its 16-year presence in the capital market [1] Financial Misconduct - China Evergrande inflated its revenue by over 560 billion yuan in 2019 and 2020, with a total of 564.15 billion yuan in inflated revenue and 92.01 billion yuan in inflated profits [2] - The former Vice Chairman and President, Xia Haijun, was fined 15 million yuan and banned for life from the securities market due to his role in the financial misconduct [2] Debt Situation - As of June 30, 2023, China Evergrande's total liabilities amounted to 2.39 trillion yuan, total assets were 1.74 trillion yuan, and net assets were -644.2 billion yuan, indicating a severe financial crisis [2] Legal and Operational Developments - The chairman, Xu Jiayin, has been taken into custody for suspected illegal activities, and former executives have also faced legal actions [3] - China Evergrande has filed for liquidation in Hong Kong, with the court ruling that only statutory creditors can participate in the liquidation process, excluding economic interest holders [4] Asset Management - The liquidators revealed that Evergrande has less than 10 billion HKD in overseas assets available for disposal, including shares in Evergrande Property and stakes in Evergrande Auto [4] - Legal actions have been initiated to recover 6 billion USD in dividends and salaries from former executives, including Xu Jiayin and his ex-wife [4] Market Valuation - Once valued at 400 billion HKD in 2017, China Evergrande's market capitalization has plummeted to approximately 2.15 billion HKD, reflecting a significant decline in investor confidence [6]